Biotech RadarJobs updated

COMPANY

Pulse Biosciences, Inc.

HQ: Hayward, CA source · pulsebiosciences.com ↗ · West Coast

FDA-cleared device company

Also known as Pulse Biosciences · 13 open jobs · last seen Oct 23, 2026 · 17 sources

Keywords: cardiovascular Skin Lesion Skin Abnormalities Sebaceous Hyperplasia Atrial Fibrillation Ablation Atrial Fibrillation Paroxysmal Cardiac Ablation Cardiac Arrhythmia Warts Warts Hand Verruca Lesion Skin Seborrheic Keratosis Maze Procedure Thyroid Nodule Thyroid Goiter Surgery Ablation of Atrial Fibrillation Clamp Study Thyroid Nodule (Benign) Benign Skin Tumor BCC - Basal Cell Carcinoma Excision Margin pancreatic cancer Nano-Pulse Stimulation CellFX nsPFA Cardiac Catheter System CellFX nano-pFA 360 Endocardial Ablation Catheter System nPulse Vybrance Percutaneous Electrode System CellFX® Percutaneous Electrode (PE) System CellFX System

Profile checked Oct 10, 2026

13Open jobs14Trials (company is sponsor)1NIH grants

Hiring

TitleLocation (from posting)Employer postedFirst seen
GENERAL JOB APPLICATIONHayward, CAOct 20, 2026Oct 21, 2026
Principal Software Quality EngineerHayward, CA - OnsiteOct 19, 2026Oct 20, 2026
Principal Quality EngineerHayward, CA - OnsiteOct 19, 2026Oct 20, 2026
Principal Global Regulatory Affairs SpecialistHayward, CA - OnsiteOct 19, 2026Oct 20, 2026
Director, Clinical Affairs - Minimally Invasive Surgery MarketHayward, CA - HybridOct 15, 2026Oct 16, 2026

See all 13 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (13 open jobs at last check). source ↗
  2. Trial start Not phased (device or behavioral study): NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System source ↗
  3. Partnership Partnership / licensing announced Dec 9, 2025. Source: SEC filing. source ↗
  4. Trial start Not phased (device or behavioral study): CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation source ↗
  5. Trial start Not phased (device or behavioral study): Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System source ↗
  6. Trial start Not phased (device or behavioral study): CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation source ↗
  7. Trial start Not phased (device or behavioral study): CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation source ↗
  8. Trial start Not phased (device or behavioral study): CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules source ↗
  9. Trial start Not phased (device or behavioral study): CellFX Treat & Resect Low-Risk BCC Feasibility Study source ↗
  10. Trial start Not phased (device or behavioral study): CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts source ↗
  11. Trial start Not phased (device or behavioral study): Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions source ↗
  12. Trial start Not phased (device or behavioral study): CellFX System for the Treatment of Cutaneous Non-Genital Warts source ↗
  13. Trial start Not phased (device or behavioral study): Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study source ↗
  14. Trial start Not phased (device or behavioral study): Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study source ↗
  15. Trial start Not phased (device or behavioral study): Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia source ↗
  16. Trial start Not phased (device or behavioral study): Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 13

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
GENERAL JOB APPLICATIONHayward, CAOct 20, 2026Oct 21, 2026Not stated
Principal Software Quality EngineerHayward, CA - OnsiteOct 19, 2026Oct 20, 2026Not stated
Principal Quality EngineerHayward, CA - OnsiteOct 19, 2026Oct 20, 2026Not stated
Principal Global Regulatory Affairs SpecialistHayward, CA - OnsiteOct 19, 2026Oct 20, 2026Not stated
Director, Clinical Affairs - Minimally Invasive Surgery MarketHayward, CA - HybridOct 15, 2026Oct 16, 2026Not stated
Sr. Systems AdministratorHayward, CA - OnsiteOct 15, 2026Oct 16, 2026Not stated
Sr. Software Test Automation EngineerHayward, CA - OnsiteOct 8, 2026Oct 8, 2026Senior
Sr. Manager, Clinical Site DevelopmentUS RemoteOct 7, 2026Oct 7, 2026Senior
Corporate Paralegal/Sr. Corporate ParalegalHayward, CAOct 6, 2026Oct 7, 2026Mid
Sr. Process Development Engineer, Catheter EngineeringHayward, CA - OnsiteSep 14, 2026Oct 5, 2026Senior
Sr. Clinical Research Associate (Cardiac Catheter Products)US RemoteSep 9, 2026Oct 5, 2026Senior
Sr. Clinical Research Associate (Soft Tissue Ablation)US RemoteAug 11, 2026Oct 5, 2026Senior
Sr. Bioengineer, Preclinical Development (In Vivo)Hayward, CA - OnsiteJul 30, 2026Oct 5, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Last 2 years.

Clinical trials (lead sponsor) 14

RecordTitlePhaseStatusStartPrimary completion
NCT06959121CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial FibrillationNot phased (device or behavioral study)RecruitingOct 23, 20252027-04 (estimated)
NCT07018596NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX SystemNot phased (device or behavioral study)RecruitingApr 6, 20262026-10 (estimated)
NCT06696170CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial FibrillationNot phased (device or behavioral study)RecruitingJul 25, 2024Jun 25, 2026 (estimated)
NCT07287176Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode SystemNot phased (device or behavioral study)RecruitingAug 21, 2025Jun 30, 2026 (estimated)
NCT06355063CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial FibrillationNot phased (device or behavioral study)RecruitingJul 31, 2024Dec 31, 2026 (estimated)
NCT06117085CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid NodulesNot phased (device or behavioral study)CompletedApr 13, 2023Nov 18, 2024 (actual)
NCT04539886Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) LesionsNot phased (device or behavioral study)CompletedSep 28, 2020Feb 2, 2021 (actual)
NCT03612570Nano-Pulse Stimulation (NPS) in Sebaceous HyperplasiaNot phased (device or behavioral study)CompletedJun 28, 2018Sep 5, 2018 (actual)
NCT04738734CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common WartsNot phased (device or behavioral study)CompletedFeb 16, 2021Dec 15, 2021 (actual)
NCT04249115Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization StudyNot phased (device or behavioral study)TerminatedFeb 5, 2019Aug 13, 2020 (actual)
NCT04253418Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization StudyNot phased (device or behavioral study)TerminatedDec 20, 2018May 14, 2020 (actual)
NCT03846531Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis StudyNot phased (device or behavioral study)CompletedMay 4, 2017Nov 13, 2017 (actual)
NCT04554394CellFX System for the Treatment of Cutaneous Non-Genital WartsNot phased (device or behavioral study)CompletedJul 17, 2019Jun 9, 2020 (actual)
NCT04918381CellFX Treat & Resect Low-Risk BCC Feasibility StudyNot phased (device or behavioral study)CompletedJun 2, 2021Mar 2, 2022 (actual)

NIH awards 1

Annual award amounts. Total $303K.

Feedback